Intradermal MVA vaccinations provide superior protection compared to intramuscular MVA vaccinations against a homologous tier 2 SHIV challenge

Authors

V S. Bollimpelli, Emory University
P. B.J. Reddy, Emory University
S. Gangadhara, Emory University
T. Charles, Emory University
S. Burton, Emory University
C. Labranche, Duke University
G. Tharp, Emory University
T. M. Styles, Emory University
T. Legere, Emory University
S. P. Kasturi, Emory University
D. Montefiori, Duke University
G. Shaw, University of Pennsylvania
J. Moore, Cornell University
S. Bosinger, Emory University
Pamela A. Kozlowski, LSU Health Sciences Center - New OrleansFollow
B. Pulendran, Stanford University
C. Derdeyn, Emory University
E. Hunter, Emory University
R. R. Amara, Emory University

Document Type

Article

Publication Date

7-10-2020

Publication Title

Journal of the Internationals AIDS Society

Volume

23(Suppl 4)

Comments

Abstract Number: OAA0303

Recommended Citation

Bollimpelli, V S.; Reddy, P. B.J.; Gangadhara, S.; Charles, T.; Burton, S.; Labranche, C.; Tharp, G.; Styles, T. M.; Legere, T.; Kasturi, S. P.; Montefiori, D.; Shaw, G.; Moore, J.; Bosinger, S.; Kozlowski, Pamela A.; Pulendran, B.; Derdeyn, C.; Hunter, E.; and Amara, R. R., "Intradermal MVA vaccinations provide superior protection compared to intramuscular MVA vaccinations against a homologous tier 2 SHIV challenge" (2020). School of Graduate Studies Faculty Publications. 165.
https://digitalscholar.lsuhsc.edu/sogs_facpubs/165
10.1002/jia2.25547